Sana Biotechnology (SANA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $11.00 price target.
Emily Bodnar’s rating is based on the promising clinical data from Sana Biotechnology’s ongoing trial for their UP421 program, which targets type 1 diabetes. The 12-week results have shown sustained efficacy and safety, as indicated by the continued presence of C-peptide, a marker for insulin production, and the absence of immune rejection or inflammation. This data supports the potential of Sana’s hypoimmune-modified pancreatic islet cells to function without the need for immunosuppression, a significant advancement in diabetes treatment.
Moreover, the company’s strategic plans to release further data throughout the year and their intention to file an IND for their SC451 program in 2026 highlight a robust pipeline that could lead to large-scale manufacturing capabilities. These developments underscore the potential for significant future growth and innovation, justifying the Buy rating given by Emily Bodnar.
In another report released today, JMP Securities also upgraded the stock to a Buy with a $5.00 price target.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SANA in relation to earlier this year.